Equity Overview
Price & Market Data
Price: $0.281
Daily Change: +$0.0111 / 3.93%
Daily Range: $0.266 - $0.283
Market Cap: $357,629,715
Daily Volume: 732,460
Performance Metrics
1 Week: 1.59%
1 Month: 22.19%
3 Months: -1.95%
6 Months: 8.65%
1 Year: 28.20%
YTD: -6.20%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. It is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. The company's leronlimab is currently under phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. It has a collaboration with Creatv Bio. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.